Top 50 Life Science Startup Investors in Europe in December 2024

Investor	Life Science Europe investments
SOSV	20
Parkwalk Advisors	17
Sofinnova Partners	16
Oxford Science Enterprises	14
UK Innovation & Science Seed Fund	14
Bpifrance	10
Kurma Partners	9
Centre for the Development of Industrial Technology (CDTI)	8
Jonathan Milner	8
Development Bank of Wales	8
Seventure Partners	8
GM&C Life Sciences Fund	7
Syncona Partners LLP	7
Nina Capital	7
Bullnet Capital	7
Capital Cell	7
APEX Ventures	7
24 Haymarket	7
Oxford Science Enterprises	7
Idinvest Partners	6
Angels in MedCity	6
PMV	6
Verve Ventures	6
Novo Holdings	6
Archangels	6
Enterprise Ireland	6
Selvedge Venture	6
Future Planet Capital	6
Newable Private Investing	6
Scottish Enterprise	6
HTGF \| High-Tech Gruenderfonds	6
R42 Group	5
Boehringer Ingelheim Venture Fund	5
Deepbridge Capital	5
IQ Capital	5
Omnes Capital	5
IFB Innovationsstarter	5
coparion	5
Advent Life Sciences	5
Amino Collective	5
Meusinvest (Noshaq)	5
Epidarex Capital	5
AIB Seed Capital Fund	5
Amadeus Capital Partners	5
Scottish Investment Bank	5
AdBio partners	4
SR One	4
Good Seed Ventures	4
Roche Venture Fund	4
Nadav Rosenberg	4

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

Dfns — Supercharge your platform with keyless custody as a service. One API to generate secure wallets, manage your crypto, sign transactions, set up business rules, monitor security, and more.
Biolevate — Accelerating Therapeutic Innovation: AI-Enhanced Workflow Automation
Orakl Oncology — Cultivated with love by the Orakl team.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Series B, Seed
France, Switzerland, Spain

Portfolio highlights

Omnidoc — Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.
Raidium — Radiology augmented GPT to tackle the complexity of precision medicine
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Grant
Spain, United States, France

Portfolio highlights

Tebrio — At the rate that the world is growing, we’ll only have enough food to feed 50% of our future population by 2050 and introducing novel proteins into the food value chain that are rich in amino acids and use less water and arable land is the only solution forward for mankind and the planet, which is why, in 2014, Adriana Casillas and Sabas de Diegofounded Tebrio, the world’s leading carbon-negative, zero-residue insect biotechnology company, which tackles climate change and the world food crisis by breeding and transforming rich amino acid mealworms into three main co-products: (i) sustainabe premium fish, pet and animal feed (ii) biofertilizer for plant nutrition that acts as a natural pest repellent (iii) chitosan to manufacture biodegradable plastic that disolves in water. Our carbon negative pilot farm produces 500 tons of co-products a year, does not emit greenhouse gases like ammonia or methane, uses 98% less water and 90% less arable land than other animal and plant protein farms, and is the only company in our industry in Spain that has received an ISO9001 certification, which guarantees the quality of our products. Thanks to our current operations, we have secured an undisclosed Series A round, which we are using to develop a EUR 50 million insect farm that will take us from a 500 tn to a 100.000 tns production of co-products a year and will be the largest of its kind in the world. Company Key Metrics: • Tebrio has 8 industrial patents in 150 countries • Tebrio’s operations are carbon negative, zero residue, and we do not emit greenhouse gases like ammonia or methane • With the same amount of natural resources, we are able to produce 500% more protein for fishmeal and animal feed than plant protein and livestock farms • Our protein for fish and animal feed is 90% digestible, 70% protein, high in essential amino acids and unsaturated fat • Tebrio was the first certified producer in the world of mealworm protein for fish and animal feed and biofertilizer for plant nutrition • Our tech powered biofertilizer has 10x more nutrients than other organic fertilizers and thanks to its properties, acts as a natural pest repellent • We are the only Spanish company in our industry with an ISO9001 certification • We are building the world’s largest insect farm, which will produce 100.000 tons of co-products a year for animal feed and plant fertilization • We use big data and 4.0 industries to industrially produce and control the Tenebrio Molitor insect
Zeleros — Leaders in the development of hyperloop technologies, we are your new electrification & automation partner in the mobility sector.
INBRAIN Neuroelectronics — We are scientists, doctors, techies and humanity lovers, with the mission of building neuroelectronic interfaces to cure brain disorders.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Clock Bio — Clock Bio operates as a biotech company, that develops novel regenerative medicines.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.
Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Lineat Composites — We introduce a new aligned fibre material format that forms the basis of high-performance sustainable composite materials.
Llusern Scientific — Llusern specialises in rapid and affordable near-patient and POC molecular diagnostics developed to detect bacterial and viral infections.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
Siit — Siit is a modern IT service management platform. Conversational, integrated and AI-powered service desk for IT and internal operation teams. Simplify internal operations today!
Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Purespring Therapeutics — Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Resolution Therapeutics — Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Lillian Care — Lillian is building a nationwide network of health facilities in Germany.

Independent Venture Capital Firm specialized in high technology Spanish start-ups. Helping tech entrepreneurs during the early stages of their company to build successful businesses

Investment focus

Software, Information Technology, Enterprise Software
Funding Round, Seed, Series A
Spain, United States, Mexico

Portfolio highlights

MLCode — Accelerated by massive AI/ML adoption, Data is to become the most critical resource for Enterprises. MLCode vision is to protect that Data. MLCode: Data Security Automation.
Inspiration-Q — Inspiration-Q focuses on developing and commercializing software solutions inspired by quantum computing for financial applications.
Mapsi Photonics — Mapsi Photonics focuses on developing macroporous silicon infrared filters for industrial applications like gas identification and thermal vision, aiming to improve performance, cost, resolution, operational range, and environmental footprint.

Capital Cell is a pan-European crowdinvesting platform for Biotech & Life Sciences companies. Mixing VC, business angels, accredited investors and the power of the Crowd, the company is building a global meeting point for companies and researchers working, fostering and financing tomorrow’s medical science.

Investment focus

Health Care, Biotechnology, Medical
Equity Crowdfunding, Funding Round, Seed
Spain, United States, United Kingdom

Portfolio highlights

Exheus — Exheus tells everything that you need to know to take maximum care of yourself and avoid risks to your health, exheus is much more than a DNA test that only indicates which genes you have.
MediQuo — MediQuo is a hospital in your pocket, connecting patients and professionals for any health interaction. Healthcare today has 75% of unnecessary medical visits that could be taken in the distance, and the vast majority of health professionals are using messaging platforms such as WhatsApp to communicate with patients or other health professionals.MediQuo is a chat-based app specialised in health, GDPR and health data compliant, giving professionals time control, incorporating patient medical history and phone privacy. Allowing also video and audio communication. It is a place for discussion, appointments or medical consultation with your doctor or any new health professional. Also includes immediate 24/7 medical response and a network, for health information and professional discovery. We have done already 1M consultations and got 600k app downloads. Our Google Play Ratings are 4,6 (with 6k reviews). We are amongst the top health apps in Spain and Latam.
Affirma Biotech — Affirma Biotech develops new orally available immunotherapeutic drugs for the treatment of severe infections and cancer

APEX Ventures is a deep-tech and medical-focused venture capital firm.

Investment focus

Artificial Intelligence, Health Care, Software
Seed, Series A, Funding Round
Germany, United Kingdom, Austria

Portfolio highlights

GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
HyperHeat — HyperHeat is a climate tech startup, that develops a breakthrough solution for zero-carbon industrial heat at very high temperatures.
TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Angel
United Kingdom, United States

Portfolio highlights

Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.

Do and dare company

Investment focus

Software, Biotechnology, Health Care
Series A, Seed, Series B
Belgium, United States, The Netherlands

Portfolio highlights

Apideck — Integrate and monitor APIs at warp speed. Apideck is the fastest way for developers to build integrations. Connect new APIs in minutes instead of days.
Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
Orakl Oncology — Cultivated with love by the Orakl team.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inﬂammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Customs Window — Customs Window is an End-to-End Customs Clearance and Trade Solutions providing Support Services to solve challenges and operations.
The Freebird Club — The social travel club for over 50s. Homestays, local events, travel advice and more.

Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.

Investment focus

Health Care, Biotechnology, Life Science
Seed, Pre-Seed, Series A
United Kingdom, Singapore

Portfolio highlights

Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
Wittaya Aqua — A better approach to aquaculture management

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
Sedivention — Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryo catheter that ablates the gastric branches of the vagus nerve within minutes. As a one-time, minimally invasive procedure, the procedure can be performed in an outpatient setting, similarto a gastroscopy.
SRTD Biotech — SRTD Biotech is an RNA-based biotechnology company that focuses on oncology, infectious, and genetic disorders.

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, United States, Austria

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

Molyon — Molyon is creating the next-generation energy storage system: the lithium-sulfer battery. Molyon offers long-life lithium-sulfur batteries that have twice the energy density of existing lithium-ion batteries on the market.
Vsim Technology — Experience the power of next-generation physics simulations with Vsim. Our cutting-edge technology provides realistic and accurate simulations for various industries.
BMLL Technologies — BMLL Technologies Ltd. operates cloud based technology platform that offers machine learning and inference framework for common limit order book problems.

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Investment focus

Biotechnology, Software, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
The Exploration Company — For Space & Non-Space Industries.

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Investment focus

Software, SaaS, Artificial Intelligence
Seed, Funding Round, Grant
Germany, United States

Portfolio highlights

3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
Tomorrow — Tomorrow combines mobile banking with sustainability. Open your sustainable account in minutes & start protecting the climate right away.
Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Investment focus

Software, SaaS, FinTech
Series A, Seed, Series B
Germany, Switzerland, United States

Portfolio highlights

Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Argá Medtech — Novel Sine Wave Technology Promises Significant Advantages Over Existing Pulsed Field Cardiac Ablation Systems
PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today

Investment focus

Software, Artificial Intelligence, Information Technology
Series B, Seed, Series A
United Kingdom, United States, Spain

Portfolio highlights

PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
qomodo — Intelligent IOT Embedded Security. We protect commercial or industrial IOT devices from the threats of the internet. Driven by leading intelligence and machine learning, our anomaly detection allows us to protect even the simplest IOT devices.

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Astraveus — Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies.
Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
Nomic — Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels.It allowsnanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.

Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Seed, Series A, Pre-Seed
Germany, Israel, United States

Portfolio highlights

Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Investment focus

Biotechnology, Artificial Intelligence, Pharmaceutical
Seed, Pre-Seed, Series A
United Kingdom, Israel, Singapore

Portfolio highlights

thymia — Making mental health as objectively measurable as physical health.
Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Loops — Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data.